MedTrace Logo

Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation

NCT01185223 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 212

Last updated 2012-12-10

No results posted yet for this study

Summary

The objective of this study is to assess the efficacy and safety of oral valganciclovir versus intravenous ganciclovir in patients following allogenic stem cell transplantation.

Conditions

  • Allogeneic Stem Cell Transplantation

Interventions

DRUG

Valganciclovir

Valganciclovir 450mg tablet or Valganciclovir powder for oral solution 50mg/mL

DRUG

Ganciclovir

2x5mg/kg/d intravenous ganciclovir

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Pierrel Research Europe GmbH

    lead INDUSTRY

Principal Investigators

  • Hermann Einsele, Prof. Dr. · Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2012-12-31

Countries

  • Austria
  • Germany
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01185223 on ClinicalTrials.gov